Clin2
NCT06628206Possibly a fitRecruiting

Testing LPX-TI641 for rheumatoid and psoriatic arthritis

Rheumatoid Arthritis (RA)Psoriatic Arthritis (PsA)

Part of Bones, joints & muscles, Immune system & allergy, Skin clinical trials.

This trial tests a new drug, LPX-TI641, to see if it is safe and how it works in the body for people with rheumatoid arthritis or psoriatic arthritis. It may be an option if you have active joint swelling and pain despite standard treatments.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 1
Enrollment
48 people
Ages
18 years and older
Study type
Interventional

Who can take part

  • You must be 18 or older with a body mass index between 18 and 35.
  • You have rheumatoid arthritis diagnosed at least 3 months ago with at least 6 tender and 6 swollen joints, or psoriatic arthritis with at least 3 tender and 3 swollen joints plus a psoriasis patch.
  • You have been on a stable dose of a standard disease-modifying drug (like methotrexate or sulfasalazine) for at least 4 weeks, or you cannot tolerate these drugs.
  • You must not have taken certain other arthritis drugs or treatments, including biologics, JAK inhibitors, or cell-depleting therapies, within a specific time frame.
  • Women who can become pregnant must use two highly effective birth control methods; men must also use birth control with their partners.
  • You must be in generally good health with no active infections, cancer in the last 5 years (except treated skin cancer), or tuberculosis.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT07748728Not yet recruiting· Phase 2
Study of TLL-018 for rheumatoid arthritis after standard treatments fail

This study tests an investigational drug called TLL-018 for people with moderate to severe rheumatoid arthritis who have not improved enough with standard disease-modifying drugs. It aims to see if the drug can reduce joint pain and swelling.

Beijing, Beijing Municipality
NCT07377773Not yet recruiting· Phase 2
New drug for moderate-to-severe rheumatoid arthritis

This trial tests an investigational drug, QLS12010, for people with moderate-to-severe rheumatoid arthritis who have not improved enough after trying at least two other types of RA medications.

NCT06647069Recruiting· Phase 1
Testing a new drug for lupus and rheumatoid arthritis

This study tests an investigational drug called SAR448501/DR-0201 in people with active lupus or rheumatoid arthritis who have not responded well to standard treatments. The goal is to see if the drug is safe and helps control disease activity.

Brisbane, Queensland
NCT06982352Recruiting· Phase 1
Testing safety of LPX-TI641 for eczema and psoriasis

This study tests a new drug called LPX-TI641 to see if it's safe and how it works in people with atopic dermatitis (eczema) or psoriasis. If you have moderate-to-severe symptoms that haven't been helped by standard creams, you might be able to join.

Fargo, North Dakota
NCT06917742Recruiting· Phase 1
Study of CPTX2309 for rheumatoid arthritis and lupus

This trial tests an investigational drug called CPTX2309, given intravenously, for people with moderate to severe rheumatoid arthritis or systemic lupus erythematosus. It aims to see if the drug is safe and effective.

Herston, Queensland
NCT06902519Recruiting· Phase 1
Study of a new drug for rheumatoid arthritis

This trial tests an experimental drug for people with rheumatoid arthritis who have not had success with other treatments. It aims to see if the drug can help reduce joint pain and swelling.

Anniston, Alabama

Hear when a new Psoriatic Arthritis (PsA) trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.